PBH - NYSE
Prestige Consumer Healthcare Inc.
$45.44
-1.1%Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.
At a Glance
Live SnapshotPrestige Consumer Healthcare Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Excellent cash generation. The company converts earnings to cash at or above 100%, indicating high-quality earnings.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Flat FCF growth. Stable but not expanding—monitor for signs of business maturity or temporary headwinds.
Working Capital Impact
Neutral working capital impact. Changes in current assets and liabilities balanced out.
Cash Flow Quality Insight
Asset-light with strong cash conversion: Low capital requirements combined with efficient cash generation creates significant shareholder value through dividends, buybacks, or strategic investments.
Prestige Consumer Healthcare Inc. Cash Flow Statement
PBH • NYSE
| Prestige Consumer Healthcare Inc. Cash Flow Statement | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 | Mar 2012 | Mar 2011 | Mar 2010 | Mar 2009 | Mar 2008 | Mar 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | ||||||||||||||||||||
190.3M | 214.6M | 209.3M | -82.3M | 205.4M | 164.7M | 142.3M | -35.8M | 339.6M | 69.4M | 99.9M | 78.3M | 72.6M | 65.5M | 37.2M | 29.2M | 31.9M | -186.8M | 33.9M | 36.1M | |
31.3M | 30.2M | 30.7M | 32.6M | 32.1M | 30.2M | 29M | 31.8M | 33.4M | 25.8M | 23.7M | 17.7M | 13.5M | 13.2M | 10.7M | 10.1M | 13.4M | 11.2M | 14M | 13.6M | |
0.0 | 0.0 | 23.1M | -60.8M | 10M | 18.6M | 13.9M | -40.6M | -269.1M | -5.8M | 46.2M | 28.9M | 19M | 25.5M | 13.8M | 9.3M | 11M | -20M | 10.1M | 9.7M | |
10.8M | 11.2M | 14M | 12.4M | 9M | 8.5M | 7.6M | 7.4M | 8.9M | 8.1M | 10M | 6.9M | 5.1M | 3.8M | 3.1M | 3.6M | 2.1M | 2.4M | 1.1M | 655K | |
25.2M | 37.5M | 11.7M | 381.6M | 14.4M | 19.2M | 15.6M | 234.7M | 113.1M | 63.6M | 16.4M | 11.1M | 13.3M | 17M | 8.1M | 3.1M | 4.9M | 251.8M | 1.1M | 655K | |
(0.0) | (52.1M) | (59.6M) | (40.7M) | (46.6M) | (34.4M) | (30.6M) | (32.8M) | (24.4M) | (48M) | (15.4M) | -11.9M | -11M | -10.6M | -12.9M | -11.9M | -15.5M | (9.8M) | (0.0) | (0.0) | |
0.0 | -41.9M | -39.8M | -53.9M | -10.9M | -5.6M | 8.8M | -8.3M | -15.8M | -13.3M | -21.8M | 13.3M | -11.9M | 12.6M | -5.4M | 31.4M | -3.8M | 7.9M | -14.2M | 11.9M | |
257.6M | 251.5M | 248.9M | 229.7M | 259.9M | 235.6M | 217.1M | 189.3M | 210.1M | 147.8M | 174.4M | 156.3M | 111.6M | 137.6M | 67.5M | 86.7M | 59.4M | 66.7M | 45M | 71.9M | |
INVESTING ACTIVITIES | ||||||||||||||||||||
-11.2M | -8.2M | -9.6M | -7.8M | -9.6M | -22.2M | -14.6M | -10.5M | -12.5M | -3M | -3.6M | -6.1M | -2.8M | -10.3M | -606K | -655K | -673K | -481K | -521K | -540K | |
-123.7M | -9.2M | -10.6M | -3.8M | -246.9M | (0.0) | -2.8M | (65.9M) | (0.0) | -693.1M | -227M | -809.2M | -55.2M | (21.5M) | -661.6M | -275M | (8M) | -4.2M | (0.0) | -31.3M | |
-1.9M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 750K | 65.9M | 970K | 1.5M | 7.6M | 10M | 3K | 15K | -662.2M | 12K | 8M | -481K | -16K | 750K | |
-136.8M | -17.5M | -20.1M | -11.6M | -256.5M | -22.2M | -16.6M | (55.4M) | -11.6M | -694.6M | -223M | -805.3M | -58M | (11.2M) | -662.2M | -275.7M | (7.3M) | -4.7M | -537K | -31.1M | |
FINANCING ACTIVITIES | ||||||||||||||||||||
0.0 | -36.7M | -25M | -50M | 0.0 | -11.9M | -56.7M | -50M | 0.0 | -1.4M | 7.2M | -2.1M | -744K | 0.0 | 0.0 | 0.0 | 0.0 | -16K | 0.0 | -10K | |
0.0 | -139.5M | -227.8M | -137.8M | -5.6M | -251.4M | -68.5M | -200M | -209M | 569.5M | 58.9M | 656.1M | -48M | -158.1M | 633.1M | 162.1M | -60.8M | -32.9M | -52.1M | -35.3M | |
-156.3M | -51.5M | -25M | -50M | (0.0) | -11.9M | -56.7M | -50M | -1.1M | -1.4M | -2.2M | -2.1M | -744K | (0.0) | (0.0) | (0.0) | (0.0) | -16K | (0.0) | -10K | |
-156.1M | -5.8M | 11.8M | 1.9M | -2M | -16.1M | -6.2M | -2.3M | 45K | -6.2M | -12.1M | -10.7M | 7.6M | 6M | -32.7M | -852K | 0.0 | 0.0 | -7K | 0.0 | |
-156.1M | -182.1M | -241M | -185.8M | -7.6M | -279.4M | -131.4M | -249.3M | -209M | 561.9M | 54M | 643.3M | -41.2M | -152.1M | 600.4M | 161.2M | -60.8M | -32.9M | -52.1M | -35.3M | |
CASH FLOW SUMMARY | ||||||||||||||||||||
1.3M | -573K | 180K | -982K | -959K | 3.6M | -1.9M | -406K | 1.1M | -409K | 497K | -1.3M | 208K | -54K | 1K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
-34M | 51.4M | -12M | 31.3M | -5.1M | -62.5M | 67.2M | -5M | -9.3M | 14.6M | 5.9M | -7M | 12.7M | -3.3M | 5.7M | -27.8M | 5.9M | 29.1M | -7.7M | 5.6M | |
97.9M | 46.5M | 58.5M | 27.2M | 32.3M | 94.8M | 27.5M | 32.5M | 41.9M | 27.2M | 21.3M | 28.3M | 15.7M | 19M | 13.3M | 41.1M | 35.2M | 6.1M | 13.8M | 8.2M | |
63.9M | 97.9M | 46.5M | 58.5M | 27.2M | 32.3M | 94.8M | 27.5M | 32.5M | 41.9M | 27.2M | 21.3M | 28.3M | 15.7M | 19M | 13.3M | 41.1M | 35.2M | 6.1M | 13.8M | |
246.4M | 243.3M | 239.4M | 221.9M | 250.3M | 213.4M | 202.6M | 178.8M | 197.6M | 144.8M | 170.8M | 150.2M | 108.8M | 127.3M | 66.8M | 86M | 58.8M | 66.2M | 44.5M | 71.4M |
SEC Filings
PBH - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-K 10-K 2026 FY FY | May 14, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 13, 2026 | May 13, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 20, 2026 | March 19, 2026 | 2026 | |
10-Q 10-Q 2025 Q4 Q4 | February 05, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 05, 2026 | February 05, 2026 | 2026 | |
10-Q 10-Q 2025 Q3 Q3 | November 06, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 06, 2025 | November 06, 2025 | 2025 | |
10-Q 10-Q 2025 Q2 Q2 | August 07, 2025 | June 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | August 07, 2025 | August 07, 2025 | 2025 | |
DEF 14A DEF 14A 2025 N/A | June 27, 2025 | August 05, 2025 | 2025 |
Related Guides
Continue your PBH research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.